Lead-212/Bismuth-212 In Vivo Generator Based on Ultrasmall Silver Telluride Nanoparticles.

Radionuclide therapy employing alpha emitters holds great potential for personalized cancer treatment. However, certain challenges remain when designing alpha radiopharmaceuticals, including the lack of stability of used radioconjugates due to nuclear decay events. In this work, ultrasmall silver telluride nanoparticles with a core diameter of 2.

Ultrasmall Gold Nanoparticles Radiolabeled with Iodine-125 as Potential New Radiopharmaceutical.

The relatively high linear energy transfer of Auger electrons, which can cause clustered DNA damage and hence efficient cell death, makes Auger emitters excellent candidates for attacking metastasized tumors. Moreover, gammas or positrons are usually emitted along with the Auger electrons, providing the possibility of theragnostic applications. Despite the promising properties of Auger electrons, only a few radiopharmaceuticals employing Auger emitters have been developed so far.

Core-shell structured gold nanoparticles as carrier for Dy/Ho in vivo generator.

Background: Radionuclide therapy (RNT) has become a very important treatment modality for cancer nowadays. Comparing with other cancer treatment options, sufficient efficacy could be achieved in RNT with lower toxicity. β emitters are frequently used in RNT due to the long tissue penetration depth of the β particles.

Effects of High Gamma Doses on the Structural Stability of Metal-Organic Frameworks.

Four different MOFs were exposed to γ rays by a cobalt-60 source reaching a maximum dose of 5 MGy. The results showed that the MIL-100 (Cr) and MIL-100 (Fe) did not exhibit obvious structural damage, suggesting their excellent radiation stability. MIL-101 (Cr) showed good radiation stability up to 4 MGy, but its structure started degrading with increasing radiation dose.

Modelling of the Lu/Lu radionuclide generator.

In order to determine the potential of Lu/Lu radionuclide generator in Lu production it is important to establish the technical needs that can lead to a clinically acceptable Lu product quality. In this work, a model that includes all the processes and the parameters affecting the performance of the Lu/Lu radionuclide generator has been developed. The model has been based on the use of a ligand to complex Lu ions, followed by the separation of the freed Lu ions.